Agile Therapeutics, Inc.

AGRX

US00847L3087

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 20:59:59 16/07/2024 BST			5-day change	1st Jan Change
1.43 ^USD	+0.70%		0.00%	-26.67%

06-26	Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. for $10.7 million.	CI
05-15	Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Agile Therapeutics, Inc. Primary Exchange Listing will Change to Nasdaq Capital Market from Nasdaq Global Market

January 03, 2019 at 05:00 am

Effective January 03, 2019, Agile Therapeutics, Inc. primary exchange listing will change to Nasdaq Capital Market from Nasdaq Global Market.

Latest news about Agile Therapeutics, Inc.

Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. for $10.7 million.	06-25	CI
Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M	05-15	MT
Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	03-28	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index	03-27	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index	03-24	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
North American Morning Briefing : Stock Futures -2-	03-19	DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy	03-18	MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility	03-14	CI
Top Premarket Gainers	02-22	MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million	02-15	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023	02-15	CI
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023	11-09	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M	11-09	MT
North American Morning Briefing : Traders Await -2-	11-09	DJ
North American Morning Briefing : Stock Futures -2-	25/09/23	DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	22/09/23	MT
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023	09/08/23	CI
Transcript : Agile Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023	09/08/23
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q2 Revenue $5.5M	09/08/23	MT

Chart Agile Therapeutics, Inc.

Duration

Period

More charts

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AGILE THERAPEUTICS, INC.	-26.67%	9.8M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+24.19%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.73%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs